针对参与缺血再灌注(ischemia-reperfusion,I/R)的因素而采取的多种心肌保护措施和药物的研究逐渐受到人们的重视,尤其是探索启动机体内源性的保护机制已成为心血管领域研究的热点。1986年Murry等[1]首次提出了缺血预处理(ischemic preconditioning,IPC)概念,经过近20年大量的基础及临床研究,结果表明IPC是迄今已知的最强大的心肌保护方法之一[2],但由于临 Many studies on myocardial protection measures and drugs for participating in the factors of ischemia-reperfusion (I / R) have drawn more and more attention. Especially, the research on the mechanism of protection that initiates the endogenous of the body has become a cardiovascular Hot spots in field research. In 1986, Murry et al [1] first proposed the concept of ischemic preconditioning (IPC). After nearly 20 years of extensive basic and clinical studies, the results show that IPC is one of the most powerful myocardial protection methods known so far [2], but due to Pro